Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.47, while Vertex Pharmaceuticals Incorporated trades at $485.5 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMLC | VRTX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $26.59 | $529.59 |
52-Week Low | $24.83 | $366.54 |
Market Cap | — | $121.09B |
Enterprise Value | — | $115.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $25.47, showing minimal daily movement with a slight decline of 0.04%. Technical indicators signal a bullish trend with moving averages supporting upward momentum, while oscillators remain neutral. The ETF maintains consistent dividend payments of $0.14 per share throughout 2026, providing steady income. Recent news highlights growing institutional interest in emerging market bonds as investors seek yield above Treasury rates.
The outlook for EMLC appears favorable given the Federal Reserve's accommodative stance and emerging market debt's attractive yield premium. However, currency risk and capital erosion concerns persist as short interest has surged 73%, indicating skepticism about long-term sustainability despite the 6.1% trailing yield.
Vertex Pharmaceuticals (VRTX) trades at $481.35, up 1.06% today, and is near its 52-week high. The stock shows a bullish technical signal with support at $471 and resistance at $482. Fundamentally, the company reported strong 2025 results with $12.0B revenue and $4.0B net income, though 2024 saw a loss. The recent $10B acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology pipeline, potentially adding $5B in peak sales.
Outlook remains positive with analyst consensus at 'Buy' and a $538 price target, implying 12% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments. Earnings growth and pipeline expansion are primary catalysts, but investors should monitor execution on acquisitions and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
